tylase (HDAC) inhibitor
Epidemiology: Multiple myeloma affects not more than 3.2 in 10,000 people in the EU, equivalent to a total of not more than 162,000 people [7]
Indication: Multiple myeloma (MM)
Additional Details: relapsed or relapsed-and-refractory
Method(s) of Administration
Oral
Company Information
Name: Novartis
US Name: Novartis
Further Information
Anticipated commissioning route (England) NHSE
High cost drug list? Awaiting Update
In NICE timetable: Yes
When: Jan / 2016
Note: www.nice.org.uk/guidance/indevelopment/gid-tag477
Implications Available only to registered users |
